Mostrar el registro sencillo del ítem
dc.contributor.author
Chantada, Guillermo Luis
dc.contributor.author
Lam, Catherine G.
dc.contributor.author
Howard, Scott C.
dc.date.available
2021-01-15T14:36:24Z
dc.date.issued
2019-02-10
dc.identifier.citation
Chantada, Guillermo Luis; Lam, Catherine G.; Howard, Scott C.; Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment; Wiley Blackwell Publishing, Inc; British Journal of Haematology; 185; 6; 10-2-2019; 1125-1135
dc.identifier.issn
0007-1048
dc.identifier.uri
http://hdl.handle.net/11336/122807
dc.description.abstract
In high-income countries, more than 90% of children with mature B-cell lymphomas are cured with frontline therapy. However, cure requires prompt and correct diagnosis, careful risk stratification, very intense chemotherapy and meticulous supportive care, together with logistical support for patients who live far from the cancer centre or face financial barriers to receiving care. In low- and middle-income countries (LMIC), cure rates range from 20% to 70% because of lack of diagnosis, misdiagnosis, abandonment of treatment, toxic death and excess relapse with reduced-intensity regimens. Fortunately, a wide range of successful interventions in LMIC have reduced these causes of avoidable treatment failure. Public awareness campaigns have led to societal awareness of childhood cancer; telepathology has improved diagnosis, even in remote areas; subsidized chemotherapy, transportation, housing and food have reduced abandonment; and hand hygiene, nurse training programmes and health system improvements have reduced toxic death. These interventions can be deployed everywhere and at low cost, so are highly scalable. Children and adolescents with Burkitt lymphoma can be cured in all countries by making a timely correct diagnosis, applying protocols adapted to the local context, preventing abandonment of therapy and avoiding toxic death. Reducing these causes of treatment failure is feasible and highly cost-effective everywhere.
dc.format
application/pdf
dc.language.iso
eng
dc.publisher
Wiley Blackwell Publishing, Inc
dc.rights
info:eu-repo/semantics/openAccess
dc.rights.uri
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.subject
ABANDONMENT
dc.subject
B-CELL LYMPHOMA
dc.subject
BURKITT LYMPHOMA
dc.subject
LOW-INCOME COUNTRIES
dc.subject
MIDDLE-INCOME COUNTRIES
dc.subject
NON-HODGKIN LYMPHOMA
dc.subject
TOXIC DEATH
dc.subject.classification
Oncología
dc.subject.classification
Medicina Clínica
dc.subject.classification
CIENCIAS MÉDICAS Y DE LA SALUD
dc.title
Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment
dc.type
info:eu-repo/semantics/article
dc.type
info:ar-repo/semantics/artículo
dc.type
info:eu-repo/semantics/publishedVersion
dc.date.updated
2021-01-13T16:21:46Z
dc.journal.volume
185
dc.journal.number
6
dc.journal.pagination
1125-1135
dc.journal.pais
Reino Unido
dc.journal.ciudad
Londres
dc.description.fil
Fil: Chantada, Guillermo Luis. Hospital Universitario Austral; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina
dc.description.fil
Fil: Lam, Catherine G.. St. Jude Children's Research Hospital; Estados Unidos
dc.description.fil
Fil: Howard, Scott C.. University of Tennessee; Estados Unidos
dc.journal.title
British Journal of Haematology
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/doi/http://dx.doi.org/10.1111/bjh.15785
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/full/10.1111/bjh.15785
dc.relation.alternativeid
info:eu-repo/semantics/altIdentifier/url/https://onlinelibrary.wiley.com/doi/epdf/10.1111/bjh.15785
Archivos asociados